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Abstract
Objective: Impulse control disorders (ICDs) and dopamine dysregulation syndrome (DDS) are important behavioral
problems that affect a subpopulation of patients with Parkinson’s disease (PD) and typically result in markedly diminished
quality of life for patients and their caregivers. We aimed to investigate the effects of subthalamic nucleus (STN) and internal
globus pallidus (GPi) deep brain stimulation (DBS) on ICD/DDS frequency and dopaminergic medication usage.
Methods: A retrospective chart review was performed on 159 individuals who underwent unilateral or bilateral PD DBS
surgery in either STN or GPi. According to published criteria, pre- and post-operative records were reviewed to categorize
patients both pre- and post-operatively as having ICD, DDS, both ICD and DDS, or neither ICD nor DDS. Group differences in
patient demographics, clinical presentations, levodopa equivalent dose (LED), and change in diagnosis following unilateral/
bilateral by brain target (STN or GPi DBS placement) were examined.
Results: 28 patients met diagnostic criteria for ICD or DDS pre- or post-operatively. ICD or DDS classification did not differ by
GPi or STN target stimulation. There was no change in DDS diagnosis after unilateral or bilateral stimulation. For ICD,
diagnosis resolved in 2 of 7 individuals after unilateral or bilateral DBS. Post-operative development of these syndromes was
significant; 17 patients developed ICD diagnoses post-operatively with 2 patients with pre-operative ICD developing DDS
post-operatively.
Conclusions: Unilateral or bilateral DBS did not significantly treat DDS or ICD in our sample, even though a few cases of ICD
resolved post-operatively. Rather, our study provides preliminary evidence that DDS and ICD diagnoses may emerge
following DBS surgery.
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Introduction
Dopamine agonist therapy and sometimes even levodopa
therapy for Parkinson’s disease (PD) may be associated with
hypersexuality, pathological gambling, compulsive eating, com-
pulsive shopping, and other ICDs [1]. In PD patients dopamine
replacement therapy may also result in a pathological overusage of
levodopa [2] and this condition has been termed the dopamine
dysregulation syndrome (DDS) [3–5]. The effects of STN and/or
GPi deep brain stimulation (DBS) on these issues remains largely
unknown, however many groups have argued that DBS,
particularly in the STN, may be beneficial for these syndromes
by simply facilitating dopamine agonist and levodopa reduction
[6,7].
Most patients undergoing DBS are selected based on the
potential for improvement of motor symptoms as well as for
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29768potential improvement in on-off medication fluctuations [8–10].
Optimal DBS candidates usually have excellent on-off dopami-
nergic responses documented by a dopamine challenge test.
Patients with earlier onset PD have been observed to experience
more severe motor fluctuations and to have a higher propensity to
develop ICDs and DDS [11,12]. These patients are more likely to
be included in DBS cohorts [13].
The existing literature is undecided as to the optimal approach
to treating patients with these debilitating behavioral disorders.
We retrospectively reviewed our comprehensive patient database
to report our experience with ICD and DDS and to specifically
examine the effect of DBS on these disorders. Neurological,
neurosurgical, neuropsychological, and psychiatric evaluations of
each patient by an interdisciplinary DBS surgical board were
carefully reviewed for ICD and DDS diagnostic criteria. The
current investigation examined the effects of unilateral and
bilateral DBS as well as lead placement (STN vs. GPi) on ICD/
DDS group classification and change in dopaminergic medication
usage for patients with idiopathic PD. The patient population was
also studied to determine whether DBS might unmask these
behavioral syndromes.
Methods
Ethics Statement
The reported study utilized a University of Florida Institutional
Review Board (UF IRB) previously approved database for PD
(INFORM-PD). The compiled data had been collected prospec-
tively on all patients seen at the University of Florida Center for
Movement Disorders & Neurorestoration. Written informed
consent was received from all participants. To facilitate the
current study, a second UF IRB approved retrospective chart
review was conducted for all patients with PD identified using the
database.
Participants
An Institutional Review Board (IRB) approved retrospective
chart review was performed on 159 patients who underwent
unilateral or bilateral DBS surgery at the University of Florida
Center for Movement Disorders & Neurorestoration between
January 2002 and January 2010. All patients operated at the
University of Florida underwent a complete in person evaluation
with a neuropsychologist, a psychiatrist, a neurologist, and a
neurosurgeon as part of the DBS screening process. The medical
records from the screening process were reviewed as well as the
records from the pre-operative interdisciplinary discussion (DBS
board) and all post-operative follow-up visits (review included
records from all four specialties).
Pre-operative and Post-operative Participant Classification – A
detailed record review was utilized to identify any pre- or post-
operative ICD or DDS. The diagnostic criteria used for DDS and
specific ICDs are detailed in Table 1. DDS was defined according
to Giovannoni’s criteria [2]. Hypersexuality was defined according
to diagnostic criteria proposed by Voon et al. [14]. Pathological
gambling was defined using the DSM-IV definition [15].
Compulsive shopping was defined using McElroy’s criteria [16].
Compulsive eating was defined according to the DSM-IV
definition and Nirenberg et al. [15,17]. Finally, punding was
defined according to Friedman who initially observed punding
behaviors, similar to those seen in individuals taking stimulants,
among patients taking levodopa medication [18]. Records were
excluded from analyses if DBS implantation occurred at an outside
institution.
Group Consensus – Two raters (S.J.M. and N.L.) served as the
primary chart reviewers. They were required to review and be
experts on the diagnostic criteria for ICDs and DDS prior to
initiating the review process. For the study data, if raters disagreed
on a diagnosis, discrepancies were resolved by tertiary expert
raters to achieve consensus before conducting final analyses.
DBS Implantation
The procedures were performed by a fellowship-trained
neurosurgeon (K.D.F.). Multiple pass microelectrode mapping
was conducted by a fellowship-trained neurologist/electrophysi-
ologist (M.S.O.). The thresholds for stimulation-induced benefit
and side effects were determined intra-operatively using macro-
stimulation via the implanted DBS lead. Each lead was placed in
the sensorimotor region of the desired target (STN or GPi). Pulse
generators were surgically implanted one month after lead
placement, and patients were typically evaluated for program-
ming and medication adjustments monthly for the first six
months, and then every 3–6 months thereafter. Patients
underwent unilateral DBS initially and were offered the addition
of a contralateral DBS implantation after 6–7 months of follow-
up if clinically indicated.
Statistical Analyses
Patients were initially separated into those with unilateral DBS
and those with bilateral DBS. In the preliminary analysis, patients
were classified based on pre-operative diagnosis (i.e. ICDs, DDS,
both DDS and ICDs, or no ICD or DDS). Diagnostic groups
were compared on demographics and particularly gender, as it
has been reported that men are predisposed to ICD and DDS
[11,12]. For both unilateral and bilateral DBS patients, the pre-
and post-operative diagnoses were compared to determine
whether the stimulation target (STN or GPi) had a significant
effect on the outcome, whether any new diagnosis of ICD or
DDS developed post-operatively, or whether symptoms of ICD
or DDS resolved post-operatively. Analyses used non-parametric
statistics (Kruskall-Wallace, Chi-Square). Significance was based
on alpha of .05.
Results
Of 159 participants, 24 patients (15.1%) met the diagnostic
criteria for ICD and 7 (4.4%) for DDS, either pre- or post-
operatively. Pre-operatively, 11/159 patients (6.9%) met criteria
for an impulse control disorder or dopamine dysregulation
syndrome (ICD=6/159, 3.8%; DDS=4/159, 2.5%; both ICD/
DDS=1/159, 0.6%).
Diagnostic Group Demographics and Medication Usage
Table 2 shows baseline demographics and characteristics for all
cohort patients. Pre-operative diagnostic subgroups were similar in
age of onset for PD symptoms, age at the time of surgery, and
motor score (UPDRS-III OFF MEDICATION, or UPDRS-III
ON MEDICATION) (all p.0.05). There was no significant
difference between diagnostic subgroups according to pre-
operative dopamine agonist usage (x
2(6)=6.51, ns), Hoehn and
Yahr Staging OFF MEDICATION (x
2(15)=9.51, ns), or Hoehn
and Yahr Staging ON MEDICATION (x
2(12)=3.94, ns).
Regarding pre-operative levodopa equivalent dose (LED), there
was similar LED usage between patients with ICD and DDS
(Mean 6 S.D.): ICD=734.06 mg6388.32 mg, DDS=1270.83
mg6743.76 mg; Z=21.03, ns) with the one ICD/DDS patient
demonstrating LED usage that doubled that of the other groups
(ICD/DDS=2250.00 mg). Of the 159 patients in the cohort,
ICDs and DDS after DBS
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Dopamine Dysregulation Syndrome (Giovanni 2000)
A. PD with documented levodopa responsiveness
B. Need for increasing doses of DRT in excess of those normally required to relieve
Parkinsonian symptoms and signs
C. Pattern of pathological use: expressed need for increased DRT in the presence of excessive
and significant dyskinesias despite being ‘on,’ drug hoarding or drug seeking behavior,
unwillingness to reduce DRT, absence of painful dystonias
D. Impairment in social or occupational functioning: fights, violent behavior, loss of friends,
absence from work, loss of job, legal difficulties, arguments or difficulties with family
E. Development of hypomanic, manic, or cyclothymic affective syndrome in relation to DRT
F. Development of a withdrawal state characterized by dysphoria, depression, irritability, and
anxiety on reducing the level of DRT
G. Duration of disturbance of at least 6 months
Impulse Control Disorders
Hypersexuality (Voon 2006)
A. The sexual thoughts/behaviors are excessive or an atypical change from baseline marked by 1 of the following:
1. Maladaptive preoccupation with sexual thoughts
2. Inappropriately or excessively requesting sex from spouse or
partner
3. Habitual promiscuity
4. Compulsive masturbation
5. Calls to telephone sex lines or viewing of pornography
6. Paraphilias
B. The behavior must have persisted for at least 1 month
C. The behavior causes 1 of the following:
1. Marked distress
2. Attempts to control thoughts or behavior that are unsuccessful
or result in marked anxiety or distress
3. Becomes time consuming
4. Significant interference with social or occupational functioning
D. The behavior does not occur exclusively during periods of hypomania or mania
E. If all criteria except C are fulfilled, the disorder is subsyndromal
Gambling (DSM-IV)
A. Persistent and recurrent maladaptive gambling behavior as indicated by 5 (or more) of the following:
1. Preoccupation with gambling
2. Increasing amount of money wagered
3. Repeated unsuccessful attempts to control
4. Restlessness or irritability when cutting down
5. Gambles to escape from problems or to relieve dysphoric mood
6. Chases losses
7. Lies to others about gambling
8. Performs illegal acts to finance gambling
9. Jeopardized relationships, work, or education
10. Relies on others for money
B. Does not occur exclusively during periods of hypomania or mania
Compulsive shopping (McElroy 1994)
A. Maladaptive preoccupation with buying or shopping that is manifested as impulses or behaviors
1. Are experienced as irresistible, intrusive, and/or senseless
2. Result in frequent buying of more than can be afforded, of
items that are not needed, or during longer periods of time
than intended
B. Cause marked distress, are time-consuming, significantly interfere with social or occupational functionoing, or result in financial problems
C. The behaviors do not occur exclusively during periods of hypomania or mania
ICDs and DDS after DBS
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male. This gender difference, however, did not reach statistical
significance (x
2(3)=3.33, ns).
DDS and DBS Stimulation
Table 3 shows pre- and post-operative diagnoses for each
patient with pre-operative DDS. After unilateral DBS
placement, all 5/5 patients (100%) still fulfilled the DDS
diagnostic criteria. Comparison of the effects of STN vs. GPi
s t i m u l a t i o no nD D Ss h o w e dn oc h a n g ei nD D Sd i a g n o s i s
relative to site of stimulation or pre-operative vs. 6 months
post-unilateral DBS medication consumption according to
LED level (all p.0.05).
Of the 5 unilateral patients, 4/5 later had bilateral DBS
placement. After bilateral DBS placement in the patients with pre-
operativeDDS,thediagnosisdidnotchange(4/4maintainedDDS).
Compulsive eating
(DSM-IV)
A. Recurrent episodes of binge eating, which is characterized by both of the following:
1. Eating, in a discrete period of time (e.g. within any 2-hour
period), an amount of food that is definitely larger than most
people would eat in a similar period of time under similar
circumstances
2. A sense of lack of control over eating during the episode (i.e.
feeling that one cannot stop eating or control what or how
much one is eating)
B. The binge-eating episodes are associated with three (or more) of the following:
1. Eating much more rapidly than normal
2. Eating until feeling uncomfortably full
3. Eating large amounts of food when not feeling physically
hungry
4. Eating alone because of being embarrassed by how much one
is eating
5. Feeling disgusted with oneself, depressed, or very guilty after
overeating
C. Marked distress regarding binge eating is present
D. The binge eating occurs, on average, at least 2 days a week for 6 months
E. The binge eating is not associated with the regular use of inappropriate compensatory behaviors (e.g. purging, fasting, excessive exercise) and does not
occur exclusively during the course of Anorexia Nervosa or Bulimia Nervosa
(Nirenberg 2006)
A. Uncontrollable consumption of a larger amount of food than normal in excess of that necessary to alleviate hunger
Punding (Friedman 1994)
A. Stereotypical motor behavior in which an intense fascination with repetitive, purposeless movements, such as taking apart mechanical objects, handling,
examining, and sorting common objects, or picking at oneself without stopping
DDS; Dopamine dysregulation syndrome.
ICDs; Impulse control disorders.
doi:10.1371/journal.pone.0029768.t001
Table 2. Cont.
Table 2. Baseline Demographics and Characteristics for All Patients in the Cohort.
ICD DDS ICD and DDSNo ICD or DDS Total
Significance among
subgroups
Mean age of PD (symptom) onset 44.2067.40 45.0061.00 40.00 48.8469.54 48.5469.40 F(3,141)=0.82, p=0.49
Mean age at time of surgery 58.5067.50 60.5067.14 50.00 61.6168.86 61.3968.77 F(3,155)=0.82, p=0.49
Mean UPDRS-III OFF MEDICATION 45.83619.83 43.5069.88 32.00 42.24612.10 42.35612.34 F(3,143)=0.40, p=0.75
Mean Hoehn and Yahr Staging OFF MEDICATION 3.00 3.00 2.5 2.87 2.8860.71 x
2(15)=9.51
Mean UPDRS-III ON MEDICATION 28.20610.94 20.0066.88 20.00 23.5769.11 23.6169.09 F(3,133)=0.68, p=0.56
Mean Hoehn and Yahr Staging ON MEDICATION 2.10 2.13 2.0 2.34 2.3260.44 x
2(12)=3.94
Mean pre-operative levodopa equivalent dose (mg) 734.066388.32 1270.836743.76 2250.00 877.116510.88 888.806522.32 F(3,141)=3.13, p=0.03
Pre-operative dopamine agonist usage 4/6 0/4 1/1 81/148 86/159 x
2(6)=6.51
Gender (M/F) 3/3 4/0 1/0 105/43 113/46 x
2(3)=3.33
MEDICATION; all PD medications.
doi:10.1371/journal.pone.0029768.t002
ICDs and DDS after DBS
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to limited information as one patient died in an unrelated motor
vehicle accident and another died of congestive heart failure (2/4
had LED information: preoperative=1456.22 mg61122.53 mg,
6 m post-bilateral=1175.00 mg635.36 mg). For these patients, 2/
4 had bilateral placement in the STN and 2/4 patients had bilateral
placement in the GPi.
ICD and DBS Stimulation
Table 4 shows pre- and post-operative diagnoses for each
patient with pre-operative ICD. Of the 7 patients with pre-
operative ICDs, 1 patient underwent bilateral simultaneous DBS
implantation and 6 patients underwent unilateral implantation.
4/6 patients went on to receive bilateral DBS placement. After
unilateral DBS placement, 1/6 patients (16.7%) no longer met
diagnostic criteria for ICD (placed in STN). Despite the
resolution of ICD post-operatively for one patient implanted in
the STN, the comparison of the effect of STN vs. GPi stimulation
on ICD diagnosis did not yield a significant difference between
the two targets (x
2(1)=1.20, ns), although notably the sample size
was small. Among the 6 unilateral DBS patients with pre-
operative ICD, there also was no significant difference in pre-
operative vs. 4 months post-unilateral DBS dopamine agonist
usage (x
2(1)=0.60, ns).
After bilateral placement, 2/4 patients (50%) with sufficient
follow-up did not meet the diagnostic criteria for ICD. One case
resolved after unilateral DBS and remained asymptomatic after
the second surgery. The second case resolved after the additional
contralateral DBS. There was no significant difference in pre-
operative vs. 4 months post-bilateral DBS dopamine agonist usage
(x
2(1)=2.92, ns). Among the 2 patients with resolved ICD, one
had bilateral placement in the STN, and the other had bilateral
placement in the GPi.
DBS Stimulation and Unmasking of Diagnoses
Among patients with pre-operative ICD, 2/7 subjects developed
DDS after DBS placement, as shown in Table 4. Both of these
patients were stimulated in the STN. Post-operative DDS was not
diagnosed in any patient in our cohort who did not have either
pre-operative DDS or ICD.
For ICD, among all of the DBS surgical interventions evaluated
(unilateral and bilateral), 17 patients developed ICD post-
operatively. Unilateral DBS was associated with 11/17 newly
diagnosed ICDs. Of these 11 patients, 5 went on to receive
bilateral DBS and in 4/5 patients (80%), the ICD resolved after
the addition of contralateral DBS therapy. Staged bilateral DBS
was associated with 6 new diagnoses of ICD after the second side
procedure that had not been present after unilateral DBS. For all
patients with new ICD diagnoses, there was no significant change
in pre-operative vs. 4 months post-unilateral DBS dopamine
agonist usage, pre-operative vs. 4 months post-bilateral DBS
dopamine agonist usage, pre-operative vs. 6 months post-unilateral
DBS LED level, or pre-operative vs. 6 months post-bilateral DBS
LED level (all p.0.05). Of the patients who developed ICD post-
unilateral DBS, 7/11 had lead placement in GPi and 4/11 had
placement in STN. Of the patients who developed ICD post-
bilateral DBS, 4/6 had bilateral placement in the STN and 2/6
had placement in the Gpi.
Discussion
Using the criteria described above, we identified a group of 11
individuals with pre-operative DDS, ICD, or both ICD and DDS.
Patients in this study all had interdisciplinary pre-operative
evaluations for DBS, and these evaluations included questions
addressing the criteria for diagnosing behavioral disorders. It is
important however to note that when interpreting the data from
Table 3. Did Unilateral and Bilateral DBS Lead Placement Impact the Pre-operative Diagnosis of DDS?
Patient Pre-operative Diagnosis Diagnosis after Unilateral DBS Placement* (Target)
Diagnosis after Bilateral DBS
Placement* (Targets)
1 DDS DDS (STN) **
Need for excessive DRT, frequent
rescue doses, development of withdrawal
state with dose reduction
Need for excessive DRT, frequent rescue doses,
development of withdrawal state with dose
reduction
2 DDS DDS (GPi) DDS (GPi, GPi)
Need for excessive DRT, self-medicating,
development of withdrawal state with
dose reduction
Need for excessive DRT, development of
withdrawal state with dose reduction
Need for excessive DRT, development of
withdrawal state with dose reduction
3 DDS DDS (STN) DDS (STN, STN)
Need for excessive DRT, self-medicating,
development of withdrawal state with
dose reduction
Need for excessive DRT, self-medicating,
development of withdrawal state with dose
reduction, unwilling to reduce dosage
Need for excessive DRT, self-medicating,
development of withdrawal state with dose
reduction, unwilling to reduce dosage
4 DDS DDS (STN) DDS (STN, STN)
Need for excessive DRT, unwilling to
reduce dosage, development of withdrawal
state with dose reduction
Need for excessive DRT, unwilling to reduce dosage,
development of withdrawal state with dose reduction,
increased need for DRT despite excessive dyskinesias
Need for excessive DRT despite being
able to decrease dosage, increased
need for DRT despite excessive dyskinesias
5 ICD and DDS ICD and DDS (GPi) ICD and DDS (GPi, GPi)
Pathological gambling and shopping Need for excessive DRT, excessive spending
and gambling, excessive money spent on
adult entertainment, cannot maintain finances
Need for excessive DRT, excessive spending
and gambling, excessive money spent on
adult entertainment, cannot maintain finances
*DBS unilateral or bilateral lead target(s) noted in parentheses.
**Patient did not have bilateral DBS lead placement.
DRT; dopamine replacement therapy including levodopa and/or dopamine agonists.
doi:10.1371/journal.pone.0029768.t003
ICDs and DDS after DBS
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over many years, and therefore the reported numbers could
represent an underestimate of these features.
The findings from this study suggest that unilateral or bilateral
DBS had no clear effect on DDS, even if medication reduction was
realized. Quantitating medication intake in DDS and ICD,
however, can be challenging as exact doses and intervals may
not be precisely known. The reason for the lack of precision is that
inherent to these syndromes is the potential for taking multiple
extra doses of medication. Moreover, since our center performs
unilateral DBS frequently, results should be interpreted with
caution, as bilateral DBS is associated with more medication
reduction, and in a larger sample size may have led to greater
improvement in these behavioral features.
GPi vs. STN stimulation targets had no appreciable differential
effect on DDS symptoms. In contrast to the negligible effect of
DBS on DDS symptoms, the effect of DBS on ICDs appeared
more promising. One of seven patients with ICDs prior to
surgery resolved their ICD after unilateral DBS placement and
remained without ICD after staged bilateral DBS. An additional
patient recovered from ICD after bilateral DBS. There was no
significant decrease in dopamine agonist usage after either
unilateral or bilateral DBS. This observation may be a result of
our small sample size, however our results suggest that
discontinuation of dopamine agonist usage was not completely
responsible for ICD resolution. An important limitation of this
study is that surgical target (STN vs. GPi DBS) was either
determined by enrollment in a study (NIH COMPARE trial), or
determined by interdisciplinary evaluation and expert discussion.
This evaluative process may have led to a bias of implanting one
target over another for various reasons including the potential for
medication reduction with STN DBS. Future studies will need to
include a randomized cohort.
DBS may have unmasked some behavioral issues for select
patients, or alternatively DBS may have precipitated these
behaviors. Prior to DBS surgery, 11 individuals had presentations
consistent with ICDs, DDS, or both ICDs and DDS. Though
often identified during the pre-operative assessment, the treatment
of ICD and DDS has not been established, and as such groups
performing DBS have not always specifically excluded these
patients from surgery, and have also not routinely employed
treatment programs. Data from this study would suggest it will be
important in the future to identify and to address these issues pre-
operatively if possible.
Interestingly, after either unilateral or bilateral DBS placement
2 patients displayed new diagnoses of DDS. Several patients who
had not previously met the full diagnostic criteria for ICD or DDS
met criteria for ICDs post-operatively. The emergence of post-
DBS issues is an interesting and important observation [19,20].
Potential explanations are that these behavioral issues were
present, but not appreciated during pre-operative neuropsycho-
logical and psychiatric evaluations, or alternatively that DBS
unmasked or precipitated the onset of these new symptoms.
Larger, prospective studies will be necessary to clarify whether
there is any causal relationship between DBS and the genesis or
unmasking of these behavioral disorders, as has been shown in
dopamine agonist use [1]. It should be considered that DBS may
unmask underlying behavioral features, but also that DBS may,
like medications, be capable of causing ICD or DDS. Another
limitation of this study was that there was not a standardized
approach to medication reduction post-DBS, and medication
reduction may impact the appearance of these behavioral issues.
Table 4. Did Unilateral and Bilateral DBS Lead Placement Impact the Pre-operative Diagnosis of ICD?
Patient Pre-operative Diagnosis
Diagnosis after Unilateral DBS Placement*
(Target) Diagnosis after Bilateral DBS Placement* (Targets)
1 ICD ** ICD and DDS (STN, STN)
Increased impulsivity, sexual
indiscretions, punding
Increased impulsivity, sexual indiscretions, overmedicating
with Sinemet, desire to increase dose unnecessarily
2 ICD ICD (GPi) No ICD or DDS (GPi, GPi)
Excessive gambling and spending Excessive gambling and spending
3 ICD ICD (GPi) ***
Gambling, hyperphagia,
compulsion to bake cakes
Gambling
4 ICD ICD (STN) ***
Excessive chocolate cravings, hyperphagia Increased sweet cravings, hyperphagia
5 ICD ICD (STN) ***
Excessive gambling with scratch-off
lottery tickets
Excessive spending, shopping, gambling with
scratch-off lottery tickets
6 ICD DDS (STN) DDS (STN, STN)
Excessive gambling with scratch-off
lottery tickets
Unwilling to lower dosage, development of
withdrawal state with dose reduction
Unwilling to lower dosage, development of
withdrawal state with dose reduction
7 ICD and DDS ICD and DDS (GPi) ICD and DDS (GPi, GPi)
Pathological gambling and shopping Need for excessive DRT, excessive spending
and gambling, excessive money spent on
adult entertainment, cannot maintain finances
Need for excessive DRT, excessive spending and
gambling, excessive money spent on adult
entertainment, cannot maintain finances
*DBS unilateral or bilateral lead target(s) noted in parentheses.
**Patient had simultaneous bilateral DBS lead placement. No diagnostic assessment was possible for the patient after unilateral placement.
***Patient did not have bilateral DBS lead placement.
DRT; dopamine replacement therapy including levodopa and/or dopamine agonists.
doi:10.1371/journal.pone.0029768.t004
ICDs and DDS after DBS
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literature. The DOMINION study reported a 13.6% ICD rate in
the largest cohort reported to date [1]. In comparison, of 159
participants in our study, 24 patients (15.1%) met the diagnostic
criteria for ICD and 7 (4.4%) for DDS, either pre- or post-
operatively. Slight discrepancies in rate may be explained by
differences in study designs, as well as differences between the two
populations. Patients with ICD or DDS could potentially be
excluded from DBS therapy, and therefore our numbers could also
be considered an underestimate of the prevalence of these
disorders. It will be important in the future to recruit a large
multi-center cohort, such as was done for the DOMINION study,
to further clarify DBS effects.
A comparison of the patient characteristics grouped by pre-
operative diagnosis (i.e. ICD, DDS, both ICDs and DDS, or no
ICD or DDS) demonstrated that there was no significant
difference between the pre-operative diagnostic groups based on
age of onset of PD, age at surgery, duration of symptoms prior to
surgery, UPDRS-III OFF MEDICATION, UPDRS-III ON
MEDICATION, pre-operative dopamine agonist usage, Hoehn
and Yahr Staging OFF MEDICATION, or Hoehn and Yahr
Staging ON MEDICATION. Although the DDS patients had a
higher mean pre-operative medication consumption relative to the
ICD group, this difference was not significant. These observations
are consistent with the body of literature on this subject [12]. Also,
in the DDS pre-operative group, we observed that all of the
patients within the DDS subgroup were male. This observation
suggests a strong predisposition to DDS among men and is
supported by previous literature [12]. A male predominance has
recently also been suggested for certain subtypes of ICDs [11].
The previously unappreciated prevalence of these Parkinson-
related behavioral disorders and the profound detrimental effect
that they have on the quality of life of patients and their caregivers
have resulted in a new appreciation among clinicians and
researchers of the critical need for an effective treatment for
ICD and DDS. Unfortunately, our understanding of these
disorders is limited and their clinical management remains quite
challenging. Decreasing or completely discontinuing a patients’
dopaminergic medications may reduce the impulsivity observed in
ICDs and may also aid in mitigating the pathological medication
usage seen in DDS. This approach, however, predictably
exacerbates Parkinsonian motor symptoms [21]. When these
measures fail, psychotherapeutic interventions may potentially be
implemented with some symptomatic improvement. Cognitive
behavioral therapy has also been shown to have some efficacy in
treating ICDs, such as pathological gambling [22]. Objective
research on the efficacy of psychiatric drugs, particularly for ICDs,
is limited [21]. Selective reuptake inhibitors and neuroleptics such
as clozapine and risperidone have been shown to help control
ICDs [23–25], while valproic acid and lithium have been shown to
improve ICDs on a more case-specific basis [26,27]. Larger studies
are needed to verify these potential pharmacologic effects.
Clinicians have been recently interested in studying the effects of
DBS on ICDs and/or DDS, especially since these entities have
proven to be difficult to address pharmacologically [7,19,20,28–
30]. Some studies suggest that DBS improves DDS, while others
indicate that DBS has no effect [7]. To complicate matters, while
some studies indicate that DBS may be an effective therapy for
ICDs, others suggest that it promotes their development
[19,20,28,29]. All of these previously published studies included
only a handful of patients. Well-designed, prospective studies will
be required to elucidate the true effects of stimulation in various
basal ganglia targets and to determine whether DBS improves,
unmasks existing, or precipitates new DDS or ICDs. We suspect,
based on the current analysis, that the story is complex and will
require a much larger sample size to adequately sort out.
In conclusion, our experience indicated that neither unilateral
nor bilateral DBS in the STN or the GPi resulted in resolution of
pre-operative dopamine dysregulation syndrome. DBS did,
however, show a potential therapeutic effect in two patients with
impulse control disorders. One important observation was that
DBS appeared to unmask or alternatively precipitate ICDs in
some patients. It will be important in future studies to address the
mechanisms that may underpin DBS precipitating these disorders.
It will need to be determined whether direct limbic stimulation, or
alternatively DBS is providing a second hit to a vulnerable genetic
background or other process. Screening paradigms for DBS may
need to be enhanced to include impulsivity, gambling, and other
behavioral measures. Finally, family and spousal input seem to be
important in uncovering at risk individuals. Careful prospective
screening for these disorders and larger, prospective multi-center
studies will be necessary to clarify the effects of DBS on DDS and
ICDs. This research should address both therapeutic and
potentially deleterious effects of DBS on these disorders.
Based on currently available evidence, clinicians should not
consider unilateral or bilateral STN or GPi DBS to be a solution to
Parkinsonian ICDs or DDS. Rather, heightened sensitivity to the
significant prevalence and profound impact of these Parkinson-
related behavioral disorders is warranted along with a more
comprehensive approach to pre- and post-operative care. Patients
should be carefully screened for ICDs and DDS before and after
surgery to assess the true impact of DBS on these disorders. A
thoughtful, patient-tailored treatment strategy for ICDs and DDS
may also include judicious reduction of dopaminergic medications
and behavioral therapies.
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